Rheumatoid arthritis-associated complications during pregnancy and its effect on offspring: comprehensive review

S Rohini1, Uday Raj Sharma2, M Vinutha1

  • 1Department of Pharmacology, Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishna Road, Achit Nagar (Post), Soldevanahalli, Bengaluru, 560090, India.

PubMed

Insights

Pregnant individuals with rheumatoid arthritis face increased risks of preterm birth and preeclampsia. Careful disease management and a team approach are vital for better maternal and infant outcomes.

Area of Science:

  • Rheumatology
  • Obstetrics
  • Neonatology

Background:

  • Rheumatoid arthritis (RA) presents unique challenges during pregnancy.
  • Maternal and fetal risks associated with RA require careful consideration.
  • Existing literature highlights the need for comprehensive understanding of RA in pregnancy.

Purpose of the Study:

  • To explore the complexities of rheumatoid arthritis during pregnancy.
  • To investigate maternal and fetal risks, including adverse pregnancy outcomes.
  • To examine the impact of RA on offspring development and neonatal outcomes.

Main Methods:

  • Extensive literature review utilizing PubMed, Google Scholar, and Science Direct.
  • Inclusion of peer-reviewed studies with sufficient data on RA and pregnancy.
  • Exclusion of studies lacking adequate data or peer review.

Main Results:

  • Pregnant individuals with RA have a higher likelihood of preterm birth and preeclampsia, linked to disease activity.
  • Low birth weight and other adverse fetal/neonatal outcomes are associated with RA during pregnancy.
  • Balancing disease-modifying agents with safety and considering medication risks is crucial.

Conclusions:

  • Rheumatoid arthritis in pregnancy necessitates a personalized, multidisciplinary approach.
  • Collaboration between rheumatologists and obstetricians is essential for optimal patient care.
  • This review provides insights for clinical practice and future research on RA and pregnancy.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.4K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
305
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
276
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K